Literature DB >> 24670433

Screening, diagnosis, and treatment of post-stroke depression.

Kimberly Dwyer Hollender.   

Abstract

Depression is a common finding after an acute stroke and often interferes with the ability of the patient to participate in the rehabilitation process. A literature review was conducted to investigate the potential benefit of the early administration of antidepressant medication on the rate of depression after acute stroke. Current practices for screening and diagnosing post-stroke depression (PSD) were also reviewed. MEDLINE, CINAHL, Cochrane Library databases, and PsychInfo were searched for relevant articles published in English up to August 2012. One of the challenges identified was that although several studies suggest benefit to the addition of antidepressant medication, little consistency exists in the timing of the intervention, particularly in regards to rehabilitation. Although patients reporting fewer depressive symptoms have been shown to have higher levels of participation in post-stroke therapy, conclusions regarding the benefit of early intervention cannot be made at this time. However, several studies do suggest that, in addition to the benefit of treating PSD, different classes of antidepressant medication may actually facilitate the neural mechanisms of recovery in patients with stroke. Overall, although the current available research cannot recommend the routine administration of antidepressant medication for PSD, the current research can support the administration of this pharmaceutical intervention on an individual basis. Future research needs surrounding PSD are vast, and several questions need to be addressed before focusing on the timing and benefit of early intervention including developing a universally validated screening tool, developing a definitive definition, and establishing acceptable treatment recommendations. Once these topics are further explored, the potential for antidepressants to improve neural mechanisms of recovery can also be further investigated.

Entities:  

Mesh:

Year:  2014        PMID: 24670433     DOI: 10.1097/JNN.0000000000000047

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  7 in total

Review 1.  A Review and Conceptual Model of Dopaminergic Contributions to Poststroke Depression.

Authors:  Ansley Stanfill; Lucas Elijovich; Brandon Baughman; Yvette Conley
Journal:  J Neurosci Nurs       Date:  2016-10       Impact factor: 1.230

Review 2.  Inflammation and the Silent Sequelae of Stroke.

Authors:  Kyra J Becker
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

3.  Altered Resting-State Connectivity within Executive Networks after Aneurysmal Subarachnoid Hemorrhage.

Authors:  Monica Maher; Nathan W Churchill; Airton Leonardo de Oliveira Manoel; Simon J Graham; R Loch Macdonald; Tom A Schweizer
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

4.  Apolipoprotein E polymorphisms increase the risk of post-stroke depression.

Authors:  Xue-Bin Li; Jie Wang; An-Ding Xu; Jian-Min Huang; Lan-Qing Meng; Rui-Ya Huang; Jun-Li Wang
Journal:  Neural Regen Res       Date:  2016-11       Impact factor: 5.135

5.  Remote Ischemic Conditioning: A Novel Non-Invasive Approach to Prevent Post-Stroke Depression.

Authors:  Wenbo Zhao; Fang Jiang; Zhen Zhang; Jing Zhang; Yuchuan Ding; Xunming Ji
Journal:  Front Aging Neurosci       Date:  2017-08-08       Impact factor: 5.750

6.  Morinda officinalis oligosaccharides alleviate depressive-like behaviors in post-stroke rats via suppressing NLRP3 inflammasome to inhibit hippocampal inflammation.

Authors:  Zhifang Li; Hexiang Xu; Yi Xu; Guanfeng Lu; Qiwei Peng; Jiefang Chen; Rentang Bi; Jianzhuang Li; Shengcai Chen; Hongkai Li; Huijuan Jin; Bo Hu
Journal:  CNS Neurosci Ther       Date:  2021-09-24       Impact factor: 5.243

7.  A Study of Antidepressant Effect and Mechanism on Intranasal Delivery of BDNF-HA2TAT/AAV to Rats with Post-Stroke Depression.

Authors:  Ce Chen; Yingying Dong; Fei Liu; Chengge Gao; Cui Ji; Yonghui Dang; Xiancang Ma; Yong Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-04       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.